Alpha Teknova

Alpha Teknova, Inc. engages in the manufacture of cell culture media and supplements. It provides reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its product offerings include pre-poured media plates for cell growth and cloning, liquid cell culture media and supplements for cellular expansion, and molecular biology reagents for sample manipulation, resuspension, and purification. The company was founded by Thomas E. Davis in 1996 and is headquartered in Hollister, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Teknova reports mixed Q4 results, focuses on cost optimization

Teknova's Q4 2022 earnings call highlighted a mixed financial performance with revenue decline offset by full-year growth, emphasizing the importance of strategic investments and operational efficiency.
Challenges in profitability, including a net loss and negative adjusted EBITDA, underscore the need for cost management and revenue optimization strategies to drive sustainable growth.
Despite facing financial hurdles, Teknova's focus on balancing cost reduction with growth initiatives and maintaining liquidity sets the stage for future financial resilience and market competitiveness.

Teknova reports mixed Q1 2023 results, eyes growth opportunities

Teknova's Q1 2023 performance showed a mix of positive and negative indicators, with revenue growth and expense management as strengths, while challenges include declining total revenue and negative adjusted EBITDA. The company's focus on innovation, cost control, and market research presents opportunities for future growth and margin improvement.

TEKNOVA reports robust Q2 revenue growth amidst operational optimizations

TEKNOVA's Q2 2023 showed strong revenue growth and operational improvements.
Despite challenges, the company remains optimistic about its future growth prospects.
Strategic investments in R&D and manufacturing capabilities position TEKNOVA for long-term success.
Efforts to manage expenses and achieve free cash flow targets are key priorities.

Alpha Teknova reports Q3 revenue decline, focuses on financial stability

Alpha Teknova (TKNO) faced revenue declines in Q3 2023, with a net loss of $10.2 million and negative adjusted EBITDA of $5.5 million.
Despite challenges, the company strengthened its financial position through a direct offering, debt repayment, and cost reduction initiatives.
Teknova's focus on managing costs, cash outflows, and strategic investments underscores its commitment to financial stability and operational efficiency.
While facing performance headwinds, Teknova aims to navigate challenges and leverage opportunities for sustainable growth and improved profitability.

Teknova maintains stability, eyes growth through cost savings and partnerships

Teknova's Q4 2023 performance showed stability in revenue and operational improvements, with a focus on cost-saving initiatives and revenue guidance for 2024.
Despite challenges in Clinical Solutions and margin pressures, Teknova's strong customer service, cost reductions, and market opportunities position it for growth.
Strategic partnerships, industry-leading Net Promoter Scores, and a positive outlook on cell and gene therapy approvals present avenues for revenue enhancement and market expansion.

Alpha Teknova (TKNO) reports solid Q1 performance amidst profitability challenges

Alpha Teknova (TKNO) delivered a strong performance in Q1 2024, showcasing revenue growth, cost management success, and operational highlights.
While facing challenges with negative adjusted EBITDA and maintaining gross margin, Teknova's strengths lie in expense management, innovation, and market positioning.
Opportunities for Teknova include product launches, market stabilization, and customer base expansion, setting the stage for future growth and success.
To sustain growth, Teknova must address profitability challenges, balance expense management with revenue growth, and capitalize on market opportunities.

Alpha Teknova (TKNO) reports Q2 growth, eyes profitability without funding

Alpha Teknova (TKNO) showed improved sequential revenue and EBITDA performance in Q2 2024. The company introduced new high-margin offerings and closed a capital raise to drive profitability. Challenges include YoY revenue decline and the need for market stabilization.

Alpha Teknova (TKNO) reports robust Q3 results and outlines growth strategies

Alpha Teknova's Q3 2024 earnings call highlighted strong financial performance, growth in key segments, and ongoing efforts to enhance profitability. While facing challenges in certain revenue streams, the company remains optimistic about its outlook and strategic initiatives for the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Alpha Teknova, Inc. (NASDAQ:TKNO ) Q1 2022 Earnings Conference Call May 11, 2022 4:30 PM ET Company Participants Sara Michelmore - Head of Investor Relations, MacDougall Advisors Stephen Gunstream - President & Chief Executive Officer Matthew Lowell - Chief Financial Officer Conference Call Participants Matthew Larew - William Blair Stephanie Yan - Cowen and Company Jacob Johnson - Stephens, Inc. Operator Good day, and thank you for standing by. Welcome to the Teknova First Quarter 2022 Financial Results Conference Call.

Alpha Teknova, Inc. (TKNO) CEO Stephen Gunstream on Q1 2022 Results - Earnings Call Transcript

First quarter 2022 total revenue was $11.1 million, up 23% year-over-year Excluding Sample Transport revenue, first quarter 2022 total revenue was $11.1 million, up 37% year-over-year Strong cash position of $76.5 million supports investment in growth strategy

Teknova Reports First Quarter 2022 Financial Results

HOLLISTER, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the discovery, development, and commercialization of drug therapies, novel vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the first quarter ended March 31, 2022, on Wednesday, May 11, 2022, following the close of market.

Teknova to Report First Quarter 2022 Financial Results on May 11, 2022

Alpha Teknova's (TKNO) CEO Stephen Gunstream on Q4 2021 Results - Earnings Call Transcript

Full year 2021 total revenue was $36.9 million, up 18% year-over-year Excluding Sample Transport revenue of $1.5 million, full year 2021 total revenue was $35.4 million, up 31% year-over-year Company provides 2022 revenue guidance of $44-$48 million

Teknova Reports Fourth Quarter and Full Year 2021 Financial Results

HOLLISTER, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the discovery, development, and commercialization of drug therapies, novel vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the fourth quarter and full year 2021 on Tuesday, March 15, 2022, following the close of market.

Teknova to Report Fourth Quarter and Full Year 2021 Financial Results on March 15, 2022

Company to participate in two upcoming investor conferences in March 2022 Company to participate in two upcoming investor conferences in March 2022

Teknova Announces Preliminary Revenue of $10.0 to $10.1 Million for the Fourth Quarter 2021

HOLLISTER, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the development and production of biopharmaceutical products, including drug therapies, novel vaccines, and molecular diagnostics, today announced that it will join the Nasdaq Biotechnology Index® (Nasdaq: NBI) effective prior to market open on Monday, December 20, 2021.

Teknova to Join the Nasdaq Biotechnology Index

Alpha Teknova, Inc. (TKNO) CEO Stephen Gunstream on Q3 2021 Results - Earnings Call Transcript

$9.4 million in total revenue, up 5% year-over-year Excluding Sample Transport, total revenue was $9.3 million, up 26% year-over-year Strong cash position of $98.0 million supports investment in long-term growth strategy

Teknova Reports Third Quarter 2021 Financial Results

HOLLISTER, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the development and production of biopharmaceutical products including drug therapies, novel vaccines, and molecular diagnostics, today announced that it will report its financial results for the third quarter of 2021 on Wednesday, November 10, 2021, following the close of market.

Teknova to Report Third Quarter 2021 Financial Results on November 10, 2021

—$8.3 million in total revenue, up 38% year-over-year—

Teknova Reports Second Quarter 2021 Financial Results

HOLLISTER, Calif., June 29, 2021 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the development and production of biopharmaceutical products including drug therapies, novel vaccines, and molecular diagnostics, today announced that on June 29, 2021, it closed its previously announced initial public offering of 6,900,000 shares of its common stock, at a price to the public of $16.00 per share. The closing included 900,000 shares sold upon full exercise of the underwriters' option to purchase additional shares of common stock in the offering. All of the shares of common stock were offered and sold by Teknova.

Teknova Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Elevation Oncology

GH Research PLC

Graphite Bio

Mister Car Wash

Acurx Pharmaceuticals LLC

Missfresh Ltd

Acurx Pharmaceuticals, Alpha Teknova, Elevation Oncology, GH Research, Graphite Bio, and MissFresh are listed on the Nasdaq. Mister Car Wash is trading the New York Stock Exchange.

7 Companies Go Public Today. What Investors Need to Know.

HOLLISTER, Calif., June 24, 2021 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the development and production of biopharmaceutical products including drug therapies, novel vaccines, and molecular diagnostics, today announced the pricing of its upsized initial public offering of 6,000,000 shares of its common stock at a price to the public of $16.00 per share. Additionally, Teknova has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock are being offered and sold by Teknova.

Teknova Announces Pricing of its Upsized Initial Public Offering

Alpha Teknova has filed proposed terms for a $75 million IPO. The firm sells stock and custom reagents to biopharmaceutical and other research organizations worldwide.

News for Alpha Teknova Stock (TKNO)